Perioperative immunotherapy for resectable non-small-cell lung cancer
Xiaodong Yang , Dongliang Bian , Jie Yang , Liang Duan , Haifeng Wang , Deping Zhao , Gening Jiang , Yuming Zhu , Peng Zhang
Clinical Cancer Bulletin ›› 2024, Vol. 3 ›› Issue (1) : 4
Perioperative immunotherapy for resectable non-small-cell lung cancer
Lung cancer, of which non-small-cell lung cancer (NSCLC) is the most common type, is the leading cause of cancer-related deaths. Anatomic pulmonary resection followed by adjuvant chemotherapy is considered the standard-of-care for patients with resectable NSCLC; however, postoperative relapses and metastases remain common. Immunotherapy, mainly with immune checkpoint inhibitors, has revolutionized the treatment of patients with metastatic NSCLC. In addition, it provides a new strategy for the perioperative treatment of resectable NSCLC. Initial encouraging results have been reported from clinical studies exploring different immunotherapeutic strategies for resectable NSCLC. This review summarizes the results of the latest clinical trials evaluating various perioperative immunotherapeutic approaches aimed at improving the outcomes of patients with resectable NSCLC.
National Natural Science Foundation of China,(82203635)
Shanghai Sailing Program,(21YF1438600)
/
| 〈 |
|
〉 |
PDF
